MXPA02012713A - Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes. - Google Patents

Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.

Info

Publication number
MXPA02012713A
MXPA02012713A MXPA02012713A MXPA02012713A MXPA02012713A MX PA02012713 A MXPA02012713 A MX PA02012713A MX PA02012713 A MXPA02012713 A MX PA02012713A MX PA02012713 A MXPA02012713 A MX PA02012713A MX PA02012713 A MXPA02012713 A MX PA02012713A
Authority
MX
Mexico
Prior art keywords
diabetes
combination
treatment
agents useful
antidiabetic agents
Prior art date
Application number
MXPA02012713A
Other languages
English (en)
Spanish (es)
Inventor
Poelje Paul D Van
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of MXPA02012713A publication Critical patent/MXPA02012713A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA02012713A 2000-07-06 2001-07-05 Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes. MXPA02012713A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
PCT/US2001/021557 WO2002003978A2 (fr) 2000-07-06 2001-07-05 Combinaison d'inhibiteurs de fbpase et d'agents antidiabetiques utile pour le traitement du diabete

Publications (1)

Publication Number Publication Date
MXPA02012713A true MXPA02012713A (es) 2004-09-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012713A MXPA02012713A (es) 2000-07-06 2001-07-05 Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.

Country Status (18)

Country Link
EP (1) EP1372660A2 (fr)
JP (1) JP2004508297A (fr)
KR (1) KR100854851B1 (fr)
CN (2) CN100396283C (fr)
AU (2) AU2001273271B2 (fr)
BR (1) BR0112212A (fr)
CA (1) CA2412142A1 (fr)
CZ (1) CZ20035A3 (fr)
HU (1) HUP0301830A3 (fr)
IL (2) IL153513A0 (fr)
MX (1) MXPA02012713A (fr)
NO (1) NO20030034L (fr)
NZ (1) NZ523227A (fr)
PL (1) PL365779A1 (fr)
RU (1) RU2328308C2 (fr)
SK (1) SK62003A3 (fr)
WO (1) WO2002003978A2 (fr)
ZA (1) ZA200300044B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
MXPA02008722A (es) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
KR100989647B1 (ko) 2001-09-24 2010-10-26 오레곤 헬스 앤드 사이언스 유니버시티 식습관의 변화
WO2003057235A2 (fr) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification des habitudes alimentaires
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
PT1700856E (pt) 2003-12-26 2016-02-19 Kyowa Hakko Kirin Co Ltd Derivado de tiazole
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
CN101119748A (zh) * 2004-12-13 2008-02-06 第一三共株式会社 用于治疗糖尿病的药物组合物
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche
US20100076037A1 (en) 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114474T1 (de) * 1989-01-24 1994-12-15 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
WO1998039342A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes d'indole et d'azaindole inhibiteurs de fructose-1,6-biophosphatase
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
US6107274A (en) * 1998-03-16 2000-08-22 Ontogen Corporation Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase)
JP2002524463A (ja) * 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
AU771039B2 (en) * 1998-12-24 2004-03-11 Metabasis Therapeutics, Inc. A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
DK1741445T3 (da) * 2000-01-21 2013-11-04 Novartis Ag Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
CN1599612A (zh) 2005-03-23
AU2001273271B2 (en) 2006-01-05
ZA200300044B (en) 2004-05-06
CA2412142A1 (fr) 2002-01-17
WO2002003978A2 (fr) 2002-01-17
NO20030034D0 (no) 2003-01-03
KR20030031952A (ko) 2003-04-23
NZ523227A (en) 2005-04-29
RU2328308C2 (ru) 2008-07-10
CN100396283C (zh) 2008-06-25
IL153513A (en) 2014-07-31
KR100854851B1 (ko) 2008-08-27
NO20030034L (no) 2003-03-05
IL153513A0 (en) 2003-07-06
PL365779A1 (en) 2005-01-10
CN101301294A (zh) 2008-11-12
JP2004508297A (ja) 2004-03-18
CZ20035A3 (cs) 2003-05-14
SK62003A3 (en) 2003-09-11
HUP0301830A3 (en) 2007-10-29
BR0112212A (pt) 2003-12-30
WO2002003978A3 (fr) 2003-10-16
HUP0301830A2 (hu) 2003-11-28
AU7327101A (en) 2002-01-21
EP1372660A2 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
MXPA02012713A (es) Combinacion de inhibidores de fructosabisfosfatasas y agentes antidiabeticos, util para el tratamiento de la diabetes.
RS99204A (en) S-aryl glucoside sglt2 inhibitors and method
PL360493A1 (en) Combinations of depeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabete mellitus
WO2003042246A3 (fr) Traitement medical
WO2000038730A3 (fr) Techniques permettant d'utiliser un inhibiteur de cyclooxygenase-2 et un ou plusieurs agents antineoplasiques comme therapie combinee pour traiter les maladies neoplasiques
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
GEP20084317B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
AU2001282886A1 (en) Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
AP2004002951A0 (en) "Combination of Eplerenone and an HMG CoA Reductase Inhibitor".
UA90077C2 (uk) Антидисритмічні агенти для лікування тазового болю, що призначаються вагінально
WO2001085201A3 (fr) Utilisation d'inhibiteurs il-18 pour le traitement et/ou la prevention de l'atherosclerose
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
EP1337255A4 (fr) Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
YU34199A (sh) Primena inhibitora gastrointestinalne lipaze
WO2002070469A3 (fr) Inhibiteurs selectifs de pde3b et leurs utilisations therapeutiques
GB9804886D0 (en) Therapeutic combination
WO2001056555A3 (fr) Utilisation d'inhibiteurs de cox-2 dans le traitement de la constipation
AP2003002855A0 (en) Inhibitor of monoamine uptake.
IL139144A0 (en) Mycobacterial inhibitors
IL130500A0 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
PT1042288E (pt) Inibidores de tripeptidil peptidase
AU2003239025A1 (en) Combination of an acid secretion inhibiting agent and a reflux inhibitor for the treatment of gerd

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: METABASIS THERAPEUTICS, INC.

FA Abandonment or withdrawal